Literature DB >> 18380943

Gabexate mesilate suppresses influenza pneumonia in mice through inhibition of cytokines.

K Kosai1, M Seki, K Yanagihara, S Nakamura, S Kurihara, K Izumikawa, H Kakeya, Y Yamamoto, T Tashiro, S Kohno.   

Abstract

Gabexate mesilate is a synthetic protease inhibitor that is effective for acute pancreatitis. The effect of gabexate mesilate in influenza pneumonia in mice was investigated by examining the changes in pulmonary inflammatory cytokines and chemokines. Pathological changes in the lungs of treated mice were extremely mild, compared with changes in infected, untreated mice. Intrapulmonary levels of interleukin-6 and macrophage inflammatory protein-2 decreased in treated mice compared with untreated mice, despite similar viral titres in the lungs. Survival terms for treated and untreated groups were similar. These data indicate that gabexate mesilate has beneficial effects on influenza pneumonia, which may be due to the modulation of inflammatory cytokine/chemokine responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18380943     DOI: 10.1177/147323000803600215

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  11 in total

Review 1.  Newer influenza antivirals, biotherapeutics and combinations.

Authors:  Frederick G Hayden
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

2.  Sustained high levels of interleukin-6 contribute to the pathogenesis of enterovirus 71 in a neonate mouse model.

Authors:  Wei Xin Khong; Damian G W Foo; Scott L Trasti; Eng Lee Tan; Sylvie Alonso
Journal:  J Virol       Date:  2011-01-12       Impact factor: 5.103

3.  A Neonatal Murine Model of Coxsackievirus A6 Infection for Evaluation of Antiviral and Vaccine Efficacy.

Authors:  Zhenjie Zhang; Zhaopeng Dong; Qingjuan Wei; Michael J Carr; Juan Li; Shujun Ding; Yigang Tong; Dong Li; Weifeng Shi
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

Review 4.  Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology.

Authors:  John S Tregoning; Jürgen Schwarze
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

5.  Virulent Pseudorabies Virus Infection Induces a Specific and Lethal Systemic Inflammatory Response in Mice.

Authors:  K Laval; J B Vernejoul; J Van Cleemput; O O Koyuncu; L W Enquist
Journal:  J Virol       Date:  2018-11-27       Impact factor: 5.103

6.  Critical role of IL-1 receptor-associated kinase-M in regulating chemokine-dependent deleterious inflammation in murine influenza pneumonia.

Authors:  Masafumi Seki; Shigeru Kohno; Michael W Newstead; Xianying Zeng; Urvashi Bhan; Nicholas W Lukacs; Steven L Kunkel; Theodore J Standiford
Journal:  J Immunol       Date:  2009-12-30       Impact factor: 5.422

7.  Suppression of interleukin-6 increases enterovirus A71 lethality in mice.

Authors:  Li-Chiu Wang; Hui-Wen Yao; Chuan-Fa Chang; Shainn-Wei Wang; Shih-Min Wang; Shun-Hua Chen
Journal:  J Biomed Sci       Date:  2017-12-12       Impact factor: 8.410

8.  The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells.

Authors:  Mutsuo Yamaya; Yoshitaka Shimotai; Yukimasa Hatachi; Nadine Lusamba Kalonji; Yukiko Tando; Yasuo Kitajima; Kaori Matsuo; Hiroshi Kubo; Ryoichi Nagatomi; Seiji Hongo; Morio Homma; Hidekazu Nishimura
Journal:  Pulm Pharmacol Ther       Date:  2015-07-10       Impact factor: 3.410

Review 9.  The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment.

Authors:  Lukas Wettstein; Frank Kirchhoff; Jan Münch
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

10.  The clinically used serine protease inhibitor nafamostat reduces influenza virus replication and cytokine production in human airway epithelial cells and viral replication in mice.

Authors:  Mutsuo Yamaya; Yoshitaka Shimotai; Ayako Ohkawara; Enkhbold Bazarragchaa; Masatoshi Okamatsu; Yoshihiro Sakoda; Hiroshi Kida; Hidekazu Nishimura
Journal:  J Med Virol       Date:  2020-12-17       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.